Response to: Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure [0.03%]
反义寡核苷酸和免疫调节剂序贯治疗作为HBV功能性治愈策略的尝试及思考回应：反义寡核苷酸和免疫调节剂序贯治疗作为乙肝病毒功能性治愈策略的尝试及思考
Maria Buti,Jeong Heo,Maximilian Lee
Maria Buti
Adolescent sobriety under siege - an urgent call to protect children from alcohol harms [0.03%]
青少年 sobriety 遭受威胁——迫切需要保护儿童免受酒精伤害
Victoria T Kronsten,Frank E Murray,Shira Zelber-Sagi et al.
Victoria T Kronsten et al.
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta [0.03%]
未经治疗的慢性丁型肝炎患者的HBV RNA和HBcrAg模式差异
Elisabetta Degasperi,Caroline Scholtes,Barbara Testoni et al.
Elisabetta Degasperi et al.
Background and aim: Serum HBV RNA and HBcrAg levels have been proposed as useful biomarkers in the management of HBV patients, however their role in chronic hepatitis Delta (CHD) is currently unknown. ...
Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma [0.03%]
术切除胆道癌患者复发风险的CT-DNA监测临床评估研究
Ying Zhang,Kui Wang,Zhengji Song
Ying Zhang
Fecal Microbiota Transplantation in a Long-Standing Auto-Brewery Syndrome with Complex Symptomatology [0.03%]
难治性自动酿醇综合征的粪菌移植治疗及其复杂症状学
Marta Casañas-Martínez,Raquel Barbero-Herranz,Diana Alegre-González et al.
Marta Casañas-Martínez et al.
The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines [0.03%]
2024年更新的WHO慢性乙型肝炎预防和管理指南：主要变化及对未来主要肝脏学会临床实践指南的潜在影响
Grace Lai-Hung Wong,Maud Lemoine
Grace Lai-Hung Wong
Progress towards hepatitis B virus (HBV) global elimination has been slow and most countries are far to reach the elimination targets set up by the World Health Organization (WHO). The burden of chronic hepatitis B is mainly bear by resourc...
Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppression role of ATGL inhibitors [0.03%]
药理学上抑制ATGL作为治疗MASH的手段：ATGL抑制剂的作用远不止于脂肪酶抑制作用
Tianhao Ying,Yuxiao Han,Mengyang Liu
Tianhao Ying
Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD" [0.03%]
关于“肝静脉压力梯度可预测MASLD患者肝失代偿和肝脏相关死亡风险”的来信回复
Yuting Guan,Qiongguang Huang
Yuting Guan
Response to: Highlighting the Impact of Hormonal Factors on Hepatic Cystogenesis: Implications for Pathophysiology and Clinical Practice [0.03%]
对激素因素影响肝囊肿发生作用的回应：病理生理和临床实践意义探讨
Renée Duijzer,Tom Jg Gevers,Joost Ph Drenth
Renée Duijzer